Tofflon Science and Technology Group Co., Ltd. Class A

Tofflon Science and Technology Group Co., Ltd. Class A

SSZSE:300171
12.65
CNY
-0.12
(-0.94%)
0.40EPS
47.22P/E
12.58BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.65
2.03
2.49
2.09
2.8
2.99
3.57
4.32
6.69
8.66
7.43
6.71
6.79
6.76
Basic EPS, GAAP
0.43
0.54
0.62
0.37
0.2
0.11
0.23
0.74
1.32
1.34
0.79
0.26
0.26
0.35
Free Cash Flow per Basic Share
0.39
-0.06
0.1
0.15
-0.03
0.3
0.68
1.74
1.46
-0.76
-1.34
0.51
0.6
- -
Dividend per Share
0.17
0.16
0.25
0.12
0.26
0.02
0.03
0.15
0.22
0.39
0.33
0.24
0.11
0.15
Book Value per Share
3.81
4.1
4.52
4.61
4.76
4.82
5.02
5.73
6.88
11.71
10.36
10.19
10.36
10.46
Tangible Book Value per Share
3.65
3.82
4.22
4.29
4.45
4.53
4.75
5.48
6.48
11.04
9.79
9.56
9.77
9.89
Basic Weighted Avg Shares
619
621
624
634
615
641
634
626
627
632
760
747
771
761
Sales/Revenue/Turnover
1,021
1,259
1,556
1,328
1,725
1,917
2,264
2,708
4,192
5,469
5,642
5,010
5,233
5,145
Operating Margin (%)
26.12
26.81
24.08
17.09
10.46
5.61
9.8
21.29
26.04
19.98
13.01
7.2
6.21
8.74
Depreciation Expense
24
29
36
48
47
48
47
44
46
66
90
116
155
- -
Net Income, GAAP
266
335
387
235
123
70
146
463
828
847
600
194
200
265
Effective Tax Rate (%)
16.57
15.29
13.78
14.31
17.75
19.66
19.51
12.41
13.08
9.91
8.79
8.3
19.79
15.48
Profit Margin (%)
26.09
26.65
24.86
17.66
7.14
3.68
6.44
17.12
19.74
15.48
10.64
3.87
3.83
5.14
Working Capital
2,047
2,102
2,177
2,210
2,286
2,351
2,543
3,027
3,275
5,668
4,292
4,809
5,043
5,000
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
3
1
1
7
72
91
Total Equity
2,408
2,677
2,948
3,000
3,086
3,117
3,243
3,694
4,478
7,644
8,109
8,047
8,172
8,260
Return on Invested Capital (%)
11.98
13.52
13.79
7.65
4.55
2.98
4.85
14.2
22.2
15.28
8.41
2.54
2.71
- -
Return on Capital (%)
10.9
12.55
13.42
7.59
3.62
1.74
4.47
12.84
18.81
13.03
7.03
2.23
2.33
- -
Return on Common Equity (%)
11.72
13.53
14.13
8.1
4.16
2.34
4.72
13.72
20.89
14.39
7.84
2.47
2.55
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
25
20
23
LT Borrowings
86
90
90
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
766
766
766
Market Capitalization
10,936
8,470
12,583

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
10,195
10,078
10,502
Cash, Cash Equivalents & STI
3,686
3,911
4,078
Accounts Receivable, Net
1,634
1,591
1,654
Inventories
3,231
3,322
3,609
Total Current Liabilities
5,152
5,160
5,501
Payables & Accruals
- -
- -
- -
ST Debt
25
20
23
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.24%
19.76%
1.56%
Free Cash Flow
-126.7%
-34.54%
20.29%
Net Income, GAAP
18.25%
-2.53%
3.24%
Sales/Revenue/Turnover
14.58%
16.34%
4.45%
Total Cash Common Dividend
45.64%
8.1%
-55.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,109
1,182
1,199
1,521
5,010
2025
1,137
1,291
- -
1,529
5,233
2026
1,108
1,426
1,081
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.06
0.05
0.05
0.26
2025
0.03
0.03
- -
0.09
0.26
2026
0.04
0.11
0.12
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.24
2025
- -
0.08
- -
- -
0.11
2026
- -
0.08
0.07
- -
- -

Company Description

CEO
Xiao Dong Zheng
Full Time Employees
5,479
Sector
Producer manufacturing
Industry
Industrial machinery
Address
Building 4 Shanghai SH China 201108
IPO Date
Jan 21, 2011
Business
Tofflon Science and Technology Group Co., Ltd. (300171.SZ) manufactures and supplies pharmaceutical equipment, systems and engineering solutions for the global pharmaceutical and biotechnology industries; core products include freeze dryers, lyophilization systems, fermenters, bioreactors, centrifuges, separation and purification systems such as chromatography, ultrafiltration and nanofiltration, filling and packaging equipment, stainless steel tanks and pipe systems, inactivation systems, small molecule chemical synthesis systems, polypeptide synthesis systems, traditional Chinese medicine extraction systems, disposable reaction and filling systems, perfusion culture platforms, mRNA production platforms, gene carrier culture systems, cell and gene therapy equipment, single-use technologies and laboratory furniture; the company also provides process support, integrated manufacturing systems, pharma engineering, quality control services and contract manufacturing. Founded in 1993 and headquartered in Shanghai, China, Tofflon operates globally across more than 50 countries and regions, serving over 3,000 pharmaceutical companies with applications in liquid and lyophilized injectables, chemical APIs, bioengineering, vaccine production and pharma packaging. In 2024, the company completed a private placement of approximately US$356 million led by Shanghai Healthcare Capital and SDIC fund to expand production capacity and enhance its strategic positioning along the biopharma industry chain; in January 2025, Tofflon announced plans to co-invest 200 million yuan alongside partners including Guotou Pioneer and Junshi Biosciences in a 10 billion yuan biopharmaceutical M&A fund focused on mergers, acquisitions and industry consolidation.